CureVac

CureVac is a Germany-based biopharmaceutical company specializing in designing technology that utilizes messenger RNA (mRNA) as a data carrier which is capable of instructing the human body to create proteins to fight viruses, such as COVID-19. The company's technology has been used in multiple medical contexts such as cancer and rare diseases.

The company has both an mRNA platform and production capabilities. Its platform analyzes millions of naturally occurring sequences and houses a nucleotide sequence library where data can be utilized by the CureVac team to created a customized mRNA therapy. The company works in partnerships with other biotechnology entities, such as Lilly, CEPI, and the Bill and Melinda Gates Foundation, to operate its pipeline taking therapeutics from a pre-clinical discovery phase through Phase 2 of clinical trials before finally producing the medical product.

CureVac also produces its mRNA therapies in its own facilities. The company has Good Manufacturing Practices (GMP) and its facilities are capable of producing standardized therapeutics. Industrial manufacturing of products is possible and could be used to produce a vaccine for COVID-19, pending clinical trials.